-
-
-
-
-
-
-
Alnylam Pharma (ALNY) Tops Q4 EPS by 6c, Misses on Revenue; Offers FY26 Revenue Guidance
-
-
-
-
-
-
-
Bernstein's US Biotech 3Q25 Preview: 'Expect Beats from ALNY and REGN'
-
-
-
-
-
-
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $290 at Cantor Fitzgerald
-
-
-
-
-
-
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
-
-
-
-
-
-
Alnylam Pharma (ALNY) Announces Preliminary Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance
-
-
-
-
-
-
-
Alnylam Pharma (ALNY) Tops Q2 EPS by $1.61
-
-
-
-
-
-
-
Midday movers: Cisco slips; SoundHound AI, Super Micro rise
-
1,203,924 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

